...We Welcome You to the Zenith Epigenetics Hub withIn The AGORACOM COMMUNITY!

Zenith's BET Inhibitor ZEN-3694 is Currently Being Evaluated in Multiple Oncology Clinical Trials

Free
Message: News out - Dosing of First Cancer Patient with a Combination of ZEN-3694 + Bristol Myers Squibb’s Immune Checkpoint Inhibitor OPDIV
Reply New Message
Prev Message Back To Forum Threaded View Next Message

News out - Dosing of First Cancer Patient with a Combination of ZEN-3694 + Bristol Myers Squibb’s Immune Checkpoint Inhibitor OPDIV

posted on Feb 22, 2022 08:50AM
Log in to use the IP Check tool [?]

News article - just released.

Zenith Epigenetics Announces Dosing of First Cancer Patient with a Combination of ZEN-3694 + Bristol Myers Squibb’s Immune Checkpoint Inhibitor OPDIVO

https://www.digitaljournal.com/pr/zenith-epigenetics-announces-dosing-of-first-cancer-patient-with-a-combination-of-zen-3694-bristol-myers-squibbs-immune-checkpoint-inhibitor-opdivo

Regards,

Long

 

 

4 Recommendations
Reply New Message
Prev Message Back To Forum Threaded View Next Message
Share
Share
New Message
Please login to post a reply